Monday, 12 April 2021

4baseCare raises $2 M for expansion of genomic tests portfolio

12 March 2021 | News

Led by investors Mount Judi Ventures, growX Ventures, Season Two Ventures, First In Ventures and a few strategic angel investors

L-R- Hitesh Goswami, Kshitij Rishi

L-R- Hitesh Goswami, Kshitij Rishi

4baseCare, an Illumina Accelerator-backed precision oncology startup based in Bengaluru, has raised an investment of $2 M, led by investors Mount Judi Ventures, growX Ventures, Season Two Ventures, First In Ventures and a few strategic angel investors.

4baseCare aims to make precision oncology a standard of care in Asia by increasing the utilisation of genomic tests in oncology and is working towards developing a first of its kind, Indian population-specific gene panel that will analyse a large number of genes for cancer-associated mutations to identify optimal treatment options leading to improved outcomes. 

4baseCare will utilise the funds for expansion of the genomic tests portfolio and for increasing its geographical presence across Asia. Additionally, it will also focus on strengthening its R&D and operations.

Hitesh Goswami, CEO, 4baseCare says, “Our vision is to leverage on technology to develop affordable solutions to personalise patient care in oncology”.

Kshitij Rishi, COO, 4baseCare says, “With this capital, we will be increasing the affordability of our genomic test portfolio through research and process efficiency.”

Sherif Kottapurath, Managing Partner, MJV and Ex-CTO, Sun Microsystems says, "We are happy that in this funding round, 4baseCare was able to attract a strong consortium of investors from India and the US, which will fuel its growth across and beyond India.”

Manu Rikhye, Partner, growX Ventures said “We look forward to working with this exceptional founding team as they work towards making India healthier.”

Sajan Pillai, CEO and Managing Partner, Season Two Ventures said, “Their quest to make precision oncology more affordable and accessible contributes greatly to the growing biotech space in India & globally & we are extremely happy to support them in their journey.”

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account






Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls